How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? (Q73920178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

editorial

0 references

title

How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

P D Delmas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

1-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2800%2900301-X

7 January 2021

10.1016/S8756-3282(00)00301-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10865202%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference